Latest COVID-19 antibody detection with ‘Gold Standard’ results
The current SARS-CoV-2 pandemic has created an urgent need for rapid point-of-care diagnostic tools. Many of these tests are being developed and are achieving FDA approval. In the face of a sweeping pandemic, assays should require no specialized equipment and should have rapid and easy-to-read visual results. Researchers in North America have developed a novel assay that involves a fast and easy sample preparation protocol and yields results in under three minutes with excellent sensitivity. The team hopes to collaborate with industrial partners to leverage both the sensitivity and ease of deployment of the technology to roll out the test in highly resource-constrained environments.
The innovation is based on Rapid Vertica Flow (RVF) Technology™, a unique patented technology with high accuracy and minimal false positives. The team has developed a robust rapid test that enables highly sensitive detection of the SARS-CoV-2 virus genome that induces a strong colorimetric reaction. Because of the strength of this color change, point-of-care instant-based diagnostics do not require specialized or expensive detection instruments.
The rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis-C in just three easy steps. The Company’s tests are sold under the Reveal, Multiplo and Miriad™ brands in global markets. BioLab collaborates with the manufacturer’s European rep and is an exclusive distributor for the item #2119-REVCOTAR Antibody Test.
If you want to get a quote for Product Item #2119-REVCOTAR Antibody Test contact us on contact @ bio-lab-inc.com
Bio Laboriatories is an exclusive distributor for the antibody test kit.
* Intellectual Property Status: Patent(s) Pending
